BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Datopotamab Deruxtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Datopotamab Deruxtecan\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06417814-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06417814)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974604-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06974604)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Preventing Dato-DXd Associated Stomatitis With Dexamethaso
 ne Mouthwash\, TROPION-DM\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069746
 04
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Study of Dato-DXd With or Without Durvalumab Compared With Investig
 ator's Choice of Chemotherapy in Combination With Pembrolizumab in Patient
 s With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-ne
 gative Breast Cancer (TROPION-Breast05)\nEstimated primary completion: 28 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06103864
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Panc
 reatic and Breast Cancer\nEstimated primary completion: 1 September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 825753
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of 
 Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without
  Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Bre
 ast03)\nEstimated primary completion: 1 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05629585
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Urothelial Carcinoma.\nStudy
 : Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Age
 nts in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, First-line Study of Dato-DXd in Combinati
 on With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable G
 enomic Alterations\nEstimated primary completion: 1 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401385-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Datopotamab Deruxtecan: Phase 1 readout est. (NCT03401385)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPIO
 N-PanTumor01)\nEstimated primary completion: 1 January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03401385
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06176261-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06176261)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain 
 metAstaSEs\nEstimated primary completion: 1 January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06176261
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533826-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06533826)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or
  T-DXd: TRADE DXd\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06533826
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357597-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280104
DTEND;VALUE=DATE:20280105
SUMMARY:Datopotamab Deruxtecan: Phase 4 readout est. (NCT07357597)
DESCRIPTION:Datopotamab Deruxtecan\, phase 4\, Non-Small Cell Lung Cancer.\
 nStudy: An Open-label\, Single-arm Study of Prophylaxis for Datopotamab De
 ruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastat
 ic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Me
 tastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Canc
 er.\nEstimated primary completion: 4 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07357597
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205822-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07205822)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Dato-DXd in Inoperable or Metastatic Hormone Re
 ceptor-positive\, HER2 IHC 0 Breast Cancer\nEstimated primary completion: 
 2 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dato
 potamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07205822
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: Study of AZD9574 as
  Monotherapy and in Combination With Anti-cancer Agents in Participants Wi
 th Advanced Solid Malignancies\nEstimated primary completion: 7 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05417594
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the Ef
 ficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated pr
 imary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350097-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06350097)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label Study of First-line Osimertinib With or Wit
 hout Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-s
 mall Cell Lung Cancer\nEstimated primary completion: 21 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350097
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Ivonescimab in Combination With Dato-DXd or Osimertin
 ib in People With Non-Small Cell Lung Cancer\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopot
 amab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07535437
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04940325-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT04940325)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd\, DS-1062a) in Advanced and/or Un
 resectable Non-Small Cell Lung Cancer\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04940325
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822543-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06822543)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Single Arm\, Phase 2 Study of Datopotamab Deruxtecan\, Carboplat
 in\, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (No
 n-small Cell Lung Cancer)\nEstimated primary completion: 30 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06822
 543
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06244485-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Datopotamab Deruxtecan: Phase 1 readout est. (NCT06244485)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1.\nStudy: A Study of Valemetost
 at Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors\nEs
 timated primary completion: 1 November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06244485
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvan
 t/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negat
 ive Breast Cancer\nEstimated primary completion: 20 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06130553-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281204
DTEND;VALUE=DATE:20281205
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT06130553)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: A Study of AZD3470\
 , a PRMT5 Inhibitor\, Given as Monotherapy and in Combination in Patients 
 With MTAP Deficient Advanced/Metastatic Solid Tumors\nEstimated primary co
 mpletion: 4 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06130553
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd-based C
 ombinations in Participants With TROP2 NMR+ NSCLC\nEstimated primary compl
 etion: 16 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07941609
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291037-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07291037)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Prev
 iously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Wi
 thout Actionable Genomic Alterations\nEstimated primary completion: 29 Jan
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07291037
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC
 )\nEstimated primary completion: 6 April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Withou
 t Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\
 nEstimated primary completion: 11 May 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129993-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Datopotamab Deruxtecan: Phase 2/3 readout est. (NCT07129993)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2/3\, Urothelial Carcinoma.\nStu
 dy: Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus G
 emcitabine Plus Carboplatin or Cisplatin in Participants With Locally Adva
 nced or Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab
 -deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07129993
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: GB268 Monotherapy or Combination Therapy for Locally Adv
 anced/Metastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completio
 n: 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dat
 opotamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07738341
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-P
 anTumor04 (TP04)]\nEstimated primary completion: 30 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, Study of First-line Dato-DXd in Combinati
 on With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expr
 ession (TC ≥ 50%) and Without Actionable Genomic Alterations\nEstimated 
 primary completion: 28 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the
  First-line Treatment of Subjects With Advanced or Metastatic NSCLC Withou
 t Actionable Genomic Alterations\nEstimated primary completion: 4 March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05215340
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lu
 ng Cancer\nEstimated primary completion: 28 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Urothelial Carcinoma.\nStudy
 : An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd +
  Rilvegostomig vs SoC in Adult Participants With High-risk MIUC\nEstimated
  primary completion: 11 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: I-SPY
  TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast
  Cancer\nEstimated primary completion: December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069595-1980@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20311101
DTEND;VALUE=DATE:20311102
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07069595)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: PREDI
 CT-RD: ctDNA Surveillance in TNBC With Residual Disease\nEstimated primary
  completion: 1 November 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07069595
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
